Previous 10 |
home / stock / cmopf / cmopf news
Medtronic ([[MDT]] +0.1%) has announced that the FDA has granted the de novo clearance for GI Genius, a computer-aided detection system that used artificial intelligence ("AI") to identify colorectal polyps.Using advanced AI, it can detect the presence of precancerous lesions with a...
Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy PR Newswire DUBLIN , April 12, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) ...
Cosmo Pharmaceuticals N.V. (CMOPF): FY GAAP EPS of -€0.55.Revenue of €60.95M (-2.5% Y/Y)FY 2021 guidance: Revenues in the range of €60M-64M; total expenses in the range of €57M-59M (of which ESOP €5.9M and Depreciation & Amortisation €6....
Cosmo Full-Year Report 2020: Cosmo returns to operating profit PR Newswire DUBLIN , March 26, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) reports Full-Year results for the year ended 31 December 2020 . In 2020, Cosmo received Europea...
Invitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021 PR Newswire DUBLIN , March 19, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for...
RedHill Biopharma (NASDAQ: RDHL ) inks a binding term sheet with Dublin, Ireland-based Cosmo Pharmaceuticals N.V. ( OTC:CMOPF ) aimed at advancing/commercializing multiple products. More news on: RedHill Biopharma Ltd., Cosmo Pharmaceuticals N.V., Healthcare stocks news, Stock...
RedHill Biopharma (NASDAQ: RDHL ) is up 10% premarket after entering into an exclusive license agreement with Cosmo Pharmaceuticals N.V. ( OTC:CMOPF ) for U.S. rights to Aemcolo (rifamycin) for Traveler’s Diarrhea and a simultaneous private investment by Cosmo ...
News, Short Squeeze, Breakout and More Instantly...
Chi Mei Optoelectronics Corp Sponsored Reg S GDR Company Name:
CMOPF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file...
Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed as new Chairman of the Board. Incumbent Chairman Mauro Ajani to continue as a Board member. Additional Boar...
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence...